Have you spotted our #BigBlueDreamBus?
Click here for information

Cart 0

Have you spotted our #BigBlueDreamBus?
Click here for information

Cart 0
Children's Brain Tumor Charity

 RESEARCH

Everyone within the Paediatric Oncology field is united in the opinion that there is an urgent need for new and better treatments of childhood brain tumours. ‘High-risk’ paediatric brain tumours are the leading cause of childhood cancer death. Biological discoveries, and their translation into more tailored therapies, will be essential to future clinical advances. The primary aim of this research is to find more effective treatment for high-risk childhood brain tumours. Ultimately this will lead to better treatments for patients.

Instinct - MB

Instinct - MB

Meet Gemma Llargues, Paediatric Brain Tumour Researcher funded by Blue Skye Thinking

Meet Gemma Llargues, Paediatric Brain Tumour Researcher funded by Blue Skye Thinking

Publication in Lancet

Publication in Lancet

Paediatric Cancer Outcomes Data Collection Project

Paediatric Cancer Outcomes Data Collection Project

IMG_7126-2.jpg

Fast Facts

New research targeting high-grade childhood brain tumour announced

• INSTINCT-MB research announced by Blue Skye Thinking, Children with Cancer UK and Little Hero with over £700,000 funding

• Research to be undertaken by Newcastle University, supported by UCL Institute of Child Health and The Institute of Cancer Research

Blue Skye Thinking, alongside charity co-funders Children with Cancer UK and Little Hero, have announced their funding for a new landmark research programme with the aim of combating medulloblastoma (MB), the most common high-grade brain tumour in children.

Screenshot 2021-09-16 at 14.38.52.png
16444078_10209295455117555_930884014_o (1).jpg

Fast Facts

Lead Professor Steve Clifford
Where: Northern Institute for Cancer Research, Newcastle
When: Ongoing
Cost: £120,000

Medulloblastoma and neuroblastoma account for >30% of childhood cancer deaths
A research project focused on identifying and exploiting medulloblastoma tumour growth dependencies as a means to find novel therapeutic approaches. The study involves comprehensive screening of drug libraries, together with biological profiling, to identify drug-sensitivities in this specific group of aggressive tumours.

logo-new.png

Fast Facts

Where: CCLG
When: 2018-2019
Cost: £40k

To address key gaps in current data collection which is particularly important where children are treated outside of clinical trials. SHOCKING TRUTH - There is NO formal data collection, monitoring and sharing of side effects for Standard Treatment Guidelines used for many children suffering with cancer.

How can we LEARN if we don't SHARE?

The results of this initiative will be used by clinicians to better inform treatment decisions based on empirical survival and empirical outcomes data. By working directly with clinical teams to improve the quality of routinely submitted data, the project will also facilitate ongoing national work relating to diagnostic pathways, including late diagnosis and emergency presentation, and the potential impact on stage of disease and survival.